Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1182 participants.
Also called NCT06183931
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,182 participants
- Registry
-
NCT06183931
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Japan, Netherlands, Norway, Poland, South Korea, Spain, Sweden, Switzerland, Taiwan, Türkiye, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06183931. Randomized; quadruple masking; primary purpose treatment. Start 2024-01-11 (actual); primary completion 2027-12-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
- Acronym
- DepleTTR-CM
- Condition
- Transthyretin Amyloid Cardiomyopathy
- Intervention (Drug)
- ALXN2220
- Intervention (Drug)
- Placebo
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct06183931- Content hash
a9fcde2d9e1c1545dccfba2578b763c9cd31f8c5bce66f4b861ba874664f0556